Stockreport

FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS

FLEX PHARMA  (FLKS) 
Last flex pharma earnings: 8/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.flex-pharma.com/investor-overview
PDF -- Phase 2 Trials in ALS and CMT to Commence in the US This Quarter -- -- Prioritizing US Phase 2 COMMEND Trial; Exploratory Australian ALS Study [Read more]